NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus.
Overview
At A Glance
NSI-189 stimulates proliferation and differentiation of human hippocampal neural stem cells through a mechanism distinct from BDNF or classical antidepressants. Rodent studies show a 20% increase in hippocampal volume after 6 weeks of treatment. It is not a receptor agonist or re…
Overview
NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus. Phase 2 trials for major depressive disorder showed improvements in subjective cognitive function, depression scores, and positive affect despite not reaching primary endpoints. It has a dedicated following in the biohacking community for its reported hippocampal neurogenesis, emotional blunting reversal, and unique cognitive profile unlike any other nootropic.
Potential Research Fields
Chemical Information
IUPAC Name
benzyl N-[2-(piperazin-1-yl)pyrimidin-5-yl]carbamate
CAS Number
1270138-40-3
Molecular Formula
C16H19N5O2
Molecular Mass
313.36 g/mol
Dosing & Protocols
Unlock the dosing protocols
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- Dose, route, how often and how long
- A titration schedule
- Reconstitution and handling notes
- Stacking notes
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Research
Unlock the Research tab
Enter your email to keep reading. It is free, and it opens these tabs on every compound page in this browser.
- Safety and side effects
- A link to the PubMed results
You also get the free peptide cheat sheet by email. Unsubscribe anytime.
Have an account? Sign in
Interactions
Interaction Matrix
Contraindications
Pregnancy or breastfeeding. Active mania or bipolar disorder (limited data). Concurrent SSRI use requires medical supervision.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$84.99
—
1
1
capsule
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
NSI-189 Capsules 20 mg | capsule | capsules (20 mg)● In Stock | $84.99BEST | — | — |
Tracking since Sep 5, 2026 · 1 data point
Vendors Selling NSI-189
How we score these vendors
Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
View Full Dosage Guide →
Protocols, calculator & safety for NSI-189
Research Score
3 PubMed results
Quality Indicators
Data Completeness
88%Research Volume
Limited research available
Quick Facts
Molecular Weight
313.36 g/mol
CAS Number
1270138-40-3
Trial Phase
Phase 2
Safety Profile
Low RiskCommon Side Effects
- • Transient cognitive changes during initial use (cognitive shifting)
- • Anxiety in first weeks
- • Sleep changes
- • Emotional blunting (initial phase)
Stop Use If
- Active psychosis — hippocampal neurogenesis changes may worsen
- Bipolar disorder (monitor closely)
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What is NSI-189 used for in research?
NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus. Phase 2 trials for major depressive disorder showed improvements in subjective cognitive function, depression scores, and positive affect despite not reaching primary endpoints. It has a dedicated following in the biohacking community for its reported hippocampal neurogenesis, emotional blunting reversal, and unique cognitive profile unlike any other nootropic.
What forms does NSI-189 come in?
NSI-189 is available in capsule form.
How much does NSI-189 cost?
Prices start at $84.99 across 1 vendor.
How do I compare NSI-189 vendors?
Compare prices, payment methods, shipping, and COA scores across 1 vendor.
Research Tools
Related Compounds
View All9-Me-BC (9-Methyl-β-carboline)
NootropicsPreclinical9-Methyl--carboline (9-Me-BC) is a synthetic -carboline alkaloid that has drawn nootropic-community interest for a preclinical property that is genuinely unusual among -carbolines: in rodent and cell-culture studies it appears to stimulate the dopaminergic phenotype - raising tyrosine hydroxylase, the number of differentiated dopamine neurons and dopamine content - while also showing neuroprotective, neurorestorative and anti-inflammatory effects, plus in-vitro MAO-A/MAO-B inhibition [PMID:17913302, PMID:20374418, PMID:32285253].
Aniracetam
NootropicsApproved (Italy)Aniracetam is a pyrrolidinone in the racetam family, developed by Hoffmann-La Roche under the code Ro 13-5057.
Bemethyl (bemitil)
NootropicsApproved (Russia)Bemethyl, known in the Russian literature as bemitil and sold in the region under names including Metaprot, Bemactor and Antihot, is 2-ethylthiobenzimidazole, normally handled as the hydrobromide salt.
Bromantane
NootropicsRussia ApprovedBromantane is an atypical psychostimulant and anxiolytic developed in the 1980s at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences, originally created as an adaptogen for Soviet military and elite athletic use and later approved in Russia for the treatment of neurasthenic and asthenic disorders under the trade name Ladasten.
Cyclazodone
NootropicsPreclinicalCyclazodone is the N-cyclopropyl derivative of pemoline, a 4-oxazolidinone stimulant.
Dihexa
NootropicsPreclinicalDihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University.
Free 2026 Peptide Cheat Sheet (PDF)
38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.